Case characteristics, clinical data, and outcomes of hospitalized COVID-19 patients in Qom province, Iran: a prospective cohort study

Mohamad Amin Pourhoseingholi  
Shahid Beheshti University of Medical Sciences Research Institute for Gastroenterology and Liver Diseases  
https://orcid.org/0000-0002-0121-8031

Hosein Yousefi  
Qom University of Medical Sciences and Health Services

Hassan Fatemi Manesh  
Qom University of Medical Sciences and Health Services

Nima Najafian Motahaver  
Qom University of Medical Sciences and Health Services

Zahra Heydari  
Qom University of Medical Sciences and Health Services School of Medicine

Mehdi Azizmohammad Looha  
Shahid Beheshti University of Medical Sciences Research Institute for Gastroenterology and Liver Diseases

Nazanin Taraghikhah  
Shahid Beheshti University of Medical Sciences Research Institute for Gastroenterology and Liver Diseases

Maryam Yazdi  
Qom University of Medical Sciences and Health Services

Zahra Salami  
Qom University of Medical Sciences and Health Services

Elmira Moallemi  
Qom University of Medical Sciences and Health Services

Seyed Hasan Adeli  
adeli@muq.ac.ir  
Qom University of Medical Sciences

Research

Keywords: COVID-19, Pandemic, Iran, Risk factor, Cohort

DOI: https://doi.org/10.21203/rs.3.rs-365321/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** The outbreak of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) dates back to December 2019 in China.

Iran has been one of the most virus inflicted countries of all in which the first case of the disease was declared on 19th February, 2020 in Qom city. The aim of this study was to report demographics, signs and symptoms, laboratory findings, therapeutic approaches, and outcomes.

**Methods:** This observational cohort study was performed from 20\(^{th}\) February 2020 to 20\(^{th}\) July 2020. All patients were admitted due to WHO, CDC, and Iran's National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, signs and symptoms, paraclinical data, treatments, outcomes of disease, and finding the risk factors of death subject to COVID-19.

**Results:** Of all 2468 participants, the mean age was 57.9±17.6 years and 56.8% of patients were male. The most significant comorbidities were seen among those who have Hypertension and Diabetes Mellitus. Cough, Dyspnea, and Fever were the most frequent symptoms. 92.3% of patients received supplementary oxygen, 14.42% were admitted to ICU, and 17.2% died in hospital. The significant risk factors of death related to COVID-19 were ageing, male gender, HTN, CHF, CVA, CKD, increasing ESR, PT, WBC, liver function tests, and decreasing Oxygen saturation.

**Conclusion:** Incontinent results in the case of COVID-19 outcomes and death-related risk factors attribute to marked differences in demographics and health care systems. The patients with hazardous risk factors must be detected urgently and monitored closely to save more lives.

Background

Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) was discovered as an infectious pathologic agent following a widespread outbreak in Wuhan city, the capital of Hubei province of China, in December 2019. (1)

At the outset, fever and respiratory were deemed the major symptoms of this storage virus (2). As time went by, the virus caused other serious clinical manifestations ranging from asymptomatic or mild constitutional symptoms to life-threatening complications leading to hospitalization and even death (3).

The rapid spread of SARS-CoV-2 to other countries including Japan, USA, Italy, Russia, Iran, South Korea revealed that COVID-19 is a highly contagious disease in that it caused a pandemic (4).

Iran has been one of the most prone countries to the virus of all (2). It is approximately 1459370 identified COVID-19 patients by nasopharyngeal and oropharyngeal swabs polymerase chain reaction (PCR) test alongside with 58412 deaths (mortality rate: 4.00%) have been recorded in Iran until February 06, 2021(3). The first confirmed case of SARS-CoV-2 in Iran that was officially reported belonged to Qom, a holy city in the north-central Iran, on 19th February, 2020. At the onset of coronavirus disease-2019 (COVID-19) outburst, Qom proved to be not only the foremost city with regard to increasing number of patients and deaths among all cities in Middle East but also the source of virus transmission in this region without any and also a source of sufficient and proper virus-related awareness and studies(4).
In an observational study from China, men figured the most hospitalized cases, with a median age of 56 years, a 26% intensive care unit (ICU) admission and 28% mortality rate(5). Whereas, an Iranian article reported different figures in that the mean age of 50.75 ± 19.33 years, ICU admission and mortality rate of 8% and 10.8%, respectively were recorded(6). Definitely, various information attributes to the differences between countries in population demographic data, genetic, prevalence of comorbidities, and health care systems(7). Reporting the clinical manifestations, risk factors, and outcomes of COVID-19 is essential to improve our knowledge and managerial skills related to the patients.

There was limited information to describe the characteristics and outcomes of Iranian hospitalized patients in relation to COVID-19-. This study aims to describe detailed demographics, comorbidities, signs and symptoms, paraclinical tests, therapeutic protocols, severity of disease, death risk factors, outcomes of the hospitalized patients, and the follow up of post-discharge COVID-19 cases. The data gathered from academic health care centers in Qom, Iran, at the outset of COVID-19 pandemic crisis.

**Materials And Methods**

**Patients and study design**

This prospective cohort study was conducted at four hospitals (Kamkar, Forghani, Beheshti, and Imam Reza) affiliated with the Qom University of Medical Sciences. Kamkar hospital was the first center in the Qom to admit the first case of COVID-19 in Iran.

We prospectively traced patients who were admitted to all four hospitals from February 20 to July 20, 2020 the infectious cases were diagnosed by nasopharyngeal or oropharyngeal swab PCR tests and also chest high resolution computed tomography (HRCT) scan if indicated. All patients were admitted subject to world health organization (WHO), Centers for Disease Control and Prevention (CDC) and Iran's national guidelines. Furthermore, hypoxemia Patients received different types of therapeutic agents and respiratory facilities included nasal cannula, simple face mask, face mask with reserve bag, and intubation based on the severity of hypoxemia during hospitalization. Serious patients were admitted to ICUs while those who are required non-invasive oxygen therapy were admitted to general wards.

This cohort study was approved by the Qom University of medical sciences ethics committee (IR.MUQ.REC.1399.013). Informed contest was taken from all participants.

**Data collection**

Patients were confirmed based on their PCR test, HRCT-scan findings, and clinical presentations. Second confirming PCR tests were performed on either highly suspicious clinical presentations patients or those with false-negative PCR tests coming from insufficient sample collection. There were no cases transfer among hospitals. For readmission cases, the first admission data were recorded. The data were collected only from COVID-19 cases whose full-length hospital stay (died or discharged) was available during the study.

Two criteria including 1. $O_2$sat$\geq$93% without Oxygen support, and 2. Normal body temperature for 2-3 days without any anti-pyretic drugs were considered for discharging patients.

Patients’ demographics, comorbidities, exposure history, signs and symptoms, vital signs, laboratory data, radiological findings, therapeutic approaches, duration of hospitalization, and outcomes were documented in their
paper medical records. Afterwards, these data were collected as the standard data collection form and then rechecked by both a physician and a statistician. In case of any disagreements, they were reassessed by a third physician. A 30-day telephone investigation of post-discharged patients was taken into account after patients’ discharge. Patients were asked about the existence of symptoms, relapse of symptoms, the requirement of readmission and the occurrence of death by the telephone investigation.

Symptoms, vital signs, radiological findings, laboratory data and type of respiratory facilities were defined within the first day of admission.

**Procedures**

All data regarding demographics, exposure history, co-morbidities, signs and symptoms, Chest HRCT-scan and laboratory findings were collected within 24 hours of admission. Plus, concentrations of biomarkers of blood samples including complete blood count (CBC) diff, C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR), high-sensitivity troponin, Serum Creatinine and liver function tests were documented. Additionally, the data with respect to therapeutic interventions including supplemental oxygen (simple face mask, face mask with reserve bag, intubation), administration of anti-viral agents, anti-bacterial agents, immunomodulatory agents, Dialysis and plasmapheresis were recorded. Finally, data from post-discharge follow up was recorded.

**Laboratory investigations**

All diagnostic real-time reverse-transcriptase-polymerase chain-reaction (RT-PCR) tests of nasopharyngeal and oropharyngeal specimens were performed in all of these four hospitals.

**Outcomes**

The main outcome of this study was to define the rate of death and survive in hospitalized patients. The secondary outcomes were frequency of demographics, comorbidities, signs and symptoms, respiratory facilities (invasive or non-invasive), drugs, laboratory data, and their association with the severity of disease and mortality.

**Statistical analysis**

Descriptive statistics were regarded as mean±SD or median (interquartile range) for continuous data and frequency (percentage) for categorical data. The chi-square independent was used to determine whether there is a significant relationship between categorical variables. The independent t-test and Mann-Whitney U test were applied to compare differences of continuous variables between groups. Graphs including Euler diagram and Heat map were utilized to represent the relationship between groups and the different frequencies respectively.

The death outcome as the event of interest for survival analysis was considered the time interval between hospitalization and event (death or discharged) was deemed as the survival time. Discharged Patients were regarded as the censored cases. The single and multiple Cox regression were used to evaluate the single and adjusted effect of risk factors on the survival time. Adjusted model was chosen with the help of stepwise selection method with forward approach. Kaplan-Meier survival curve was applied to illustrate cumulative probability of occurring event of interest. All analyzes were performed by R 3.6.2. P-values less than 0.05 were considered as the statistically significant.

**Results**
2468 patients with clinical presentations, chest HRCT-scan findings that were confirmed by positive RT-PCR tests, based on Iran's national guidelines, were admitted to the hospitals between February 20 and July 20, 2020.

Table 1 summarized the baseline characteristics and their association with disease outcome (death or survive) and severity. The mean age of patients was 57.9 ± 17.6 years while the mean age of the dead was significantly higher than survivors (66.8 ± 15.0 vs 56.0 ± 17.6, p-value < 0.001). Although all age groups probable infected with SARS-CoV-2, the highest rate of infection belonged to 60–69 years age group. The mean BMI of patients was 25.4 ± 3.2 kg/m² of which 55.2% were overweight and obese, 1402 (56.8%) were men, 2291(92.9%) were Iranian and 2354 (95.4%) were non-smokers while 2167(87.8%) of cases were reported none or unknown history of exposure. 5.4% of cases had misused Antibiotics before admission.
| Variables                  | Total (n = 2468) | Disease Outcome | Ward |           |           |           |
|----------------------------|------------------|-----------------|------|-----------|-----------|-----------|
|                            |                  | Deceased (n = 424) |       | Survivor (n = 2044) | General (n = 2112) | ICU (n = 356) |
|                            |                  |                  |       |           |           |           |
| Age                        |                  |                  |       |           |           |           |
| Mean ± SD                  | 57.9 (17.6)      | 66.8 (15.0)      | 56.0 (17.6) | < 0.001<sup>a</sup> | 56.8 (19.6) | 63.9 (16.5) | < 0.001<sup>a</sup> |
| Median (Q1 - Q3)           | 59.0 (45.0–71.0) | 68.0 (58.0–78.0) | 57.0 (42.0–69.0) | < 0.001<sup>b</sup> | 58.0 (44.0–70.0) | 65.0 (53.0–77.0) | < 0.001<sup>b</sup> |
| 0–9                        | 0 (0)            | 0 (0)            | 0 (0) | < 0.001<sup>c</sup> | 0 (0)     | 0 (0)     | < 0.001<sup>c</sup> |
| 10–19                      | 34 (1.4)         | 0 (0)            | 34 (1.7) | 33 (1.6) | 1 (0.3)  |
| 20–29                      | 123 (5)          | 7 (1.7)          | 116 (5.7) | 112 (5.3) | 11 (3.1) |
| 30–39                      | 271 (11)         | 10 (2.4)         | 261 (12.8) | 251 (11.9) | 20 (5.6) |
| 40–49                      | 365 (14.8)       | 47 (11.1)        | 318 (15.6) | 327 (15.5) | 38 (10.7) |
| 50–59                      | 483 (19.6)       | 60 (14.2)        | 423 (20.7) | 422 (20)  | 61 (17.1) |
| 60–69                      | 513 (20.8)       | 101 (23.8)       | 412 (20.2) | 433 (20.5) | 80 (22.5) |
| 70–79                      | 386 (15.6)       | 111 (26.2)       | 275 (13.5) | 307 (14.5) | 79 (22.2) |
| 80–89                      | 246 (10)         | 69 (16.3)        | 177 (8.7) | 193 (9.1) | 53 (14.9) |
| 90–99                      | 47 (1.9)         | 19 (4.5)         | 28 (1.4)  | 34 (1.6)  | 13 (3.7)  |
| Gender No (%)              |                  |                  |       |           |           |           |
| Female                     | 1066 (43.2)      | 164 (38.7)       | 902 (44.1) | 913 (43.2) | 153 (43.0) |
| Male                       | 1402 (56.8)      | 260 (61.3)       | 1142 (55.9) | 11199 (56.8) | 203 (57.0) |
| Pregnancy, N (%)<sup>*</sup> |                  |                  |       |           |           |           |
| Yes                        | 32 (3.0)         | 2/164 (1.2)      | 30/902 (3.3) | 28/913 (3.1) | 6/153 (3.9%) |
| BMI                        |                  |                  |       |           |           |           |
| Mean ± SD                  | 25.4 (3.2)       | 25.6 (3.1)       | 25.3 (3.2) | 0.055<sup>a</sup> | 25.3 (3.2) | 25.5 (3.1) | 0.421<sup>c</sup> |
| Underweight ( = < 18.5)    | 10 (0.4)         | 2 (0.5)          | 8 (0.4)  | 0.043<sup>c</sup> | 9 (0.4)   | 1 (0.3)   | 0.496<sup>c</sup> |
| Variables                        | Total (n = 2468) | Disease Outcome | P-value | Ward General (n = 2112) | P-value | Ward ICU (n = 356) | P-value |
|---------------------------------|-----------------|-----------------|---------|-------------------------|---------|-------------------|---------|
|                                 |                 | Deceased (n = 424) |         | Survivor (n = 2044)    |         |                   |         |
| Normal weight (= 18.5–24.9)    | 1097 (44.4)     | 163 (38.4)       |         | 934 (45.7)              |         | 947 (44.8)        |         |
| Overweight (= 25–29.9)         | 1211 (49.1)     | 234 (55.2)       |         | 977 (47.8)              |         | 1024 (48.5)       |         |
| Obesity (30 or greater)        | 150 (6.1)       | 25 (5.9)         |         | 125 (6.1)               |         | 132 (6.3)         |         |
| Location, No (%)               |                 |                 |         |                         |         |                   |         |
| Village                        | 103 (4.2)       | 25 (5.9)         |         | 78 (3.8)                |         | 82 (3.9)          |         |
| City                           | 2365 (95.8)     | 399 (94.1)       |         | 1966 (96.2)             |         | 2030 (96.1)       |         |

P-values: c
| Variables                        | Total (n = 2468) | Disease Outcome | P-value | Ward General (n = 2112) | P-value | Ward ICU (n = 356) | P-value |
|---------------------------------|-----------------|----------------|---------|--------------------------|---------|-------------------|---------|
|                                 |                 | Deceased (n = 424) |         |                          |         |                   |         |
| Nation, N0 (%)                  |                 | Deceased (n = 424) |         |                          |         |                   |         |
| Other                           | 175 (7.1)       | 33 (7.8)         |         | 142 (7.0)                |         | 145 (6.9)         |         |
| Iran                            | 2291 (92.9)     | 391 (92.2)       |         | 1900 (93.0)              |         | 1965 (93.1)       |         |
| **Exposure History, No (%)**    |                 |                 | 0.936   |                          |         |                   | 0.800   |
| No or Unknown                   | 2167 (87.8)     | 368 (86.8)       |         | 1799 (88)                |         | 1860 (88.1)       |         |
| Household contact               | 170 (6.9)       | 36 (8.5)         |         | 134 (6.6)                |         | 143 (6.8)         |         |
| Transmission out of Home       | 125 (5.1)       | 20 (4.7)         |         | 105 (5.1)                |         | 104 (4.9)         |         |
| Travelling to China             | 6 (0.2)         | 0 (0)            |         | 6 (0.3)                  |         | 5 (0.2)           |         |
| **Comorbidity, No of yes (%)**  |                 |                 |         |                          |         |                   |         |
| Hypertension (HTN)              | 773 (31.3)      | 167 (39.4)       | < 0.001 | 606 (29.6)               | < 0.001 | 633 (30)          | < 0.001 |
| Ischemic heart disease (IHD)    | 259 (10.5)      | 49 (11.6)        | 0.443   | 210 (10.3)               | 0.496   | 218 (10.3)        | 0.547   |
| Coronary artery bypass grafting (CABG) | 71 (2.9)   | 18 (4.2)         | 0.064   | 53 (2.6)                 | 0.002   | 59 (2.8)          | 0.547   |
| Cognitive hear failure (CHF)    | 37 (1.5)        | 18 (4.2)         | < 0.001 | 19 (0.9)                 | < 0.001 | 25 (1.2)          | 0.002   |
| Asthma                          | 100 (4.1)       | 13 (3.1)         | 0.258   | 87 (4.3)                 | 0.647   | 84 (4)            |         |
| Chronic obstructive pulmonary disease (COPD) | 100 (4.1) | 30 (7.1)         | 0.001   | 70 (3.4)                 | 0.454   | 83 (3.9)          |         |
| Diabetes mellitus (DM)          | 679 (27.5)      | 145 (34.2)       | 0.001   | 534 (26.1)               | < 0.001 | 552 (26.1)        | < 0.001 |
| Pneumonia                       | 62 (2.5)        | 17 (4.0)         | 0.030   | 45 (2.2)                 | 0.137   | 49 (2.3)          |         |
| Variables                          | Total (n = 2468) | Disease Outcome | P-value | Ward General (n = 2112) | P-value |
|-----------------------------------|-----------------|-----------------|---------|-------------------------|---------|
|                                   |                 | Deceased (n = 424) | Survivor (n = 2044) |           |         |
| Cerebrovascular accident (CVA)    | 61 (2.5)        | 19 (4.5)         | 42 (2.1) | 0.003                  |         |
|                                   |                 |                  |         |                         | 47 (2.2) | 0.055  |
| Gastrointestinal (GI)             | 68 (2.8)        | 13 (3.1)         | 55 (2.7) | 0.668                  |         |
|                                   |                 |                  |         |                         | 58 (2.7) | 0.947  |
| Chronic kidney disease (CKD)      | 89 (3.6)        | 31 (7.3)         | 58 (2.8) | < 0.001                |         |
|                                   |                 |                  |         |                         | 70 (3.3) | 0.058  |
| Rheumatoid arthritis (RA)         | 76 (3.1)        | 16 (3.8)         | 60 (2.9) | 0.363                  |         |
|                                   |                 |                  |         |                         | 66 (3.1) | 0.750  |
| Cancer                            | 37 (1.5)        | 14 (3.3)         | 23 (1.1) | 0.001                  |         |
|                                   |                 |                  |         |                         | 28 (1.3) | 0.084  |
| Hyperlipidemia (HLP)              | 322 (13.0)      | 65 (15.3)        | 257 (12.6) | 0.125 |         |
|                                   |                 |                  |         |                         | 280 (13.3) | 0.449 |
| Hepatitis C virus (HCV)           | 17 (0.7)        | 4 (0.9)          | 13 (0.6) | 0.515                  |         |
|                                   |                 |                  |         |                         | 15 (0.7) | 0.754  |
| Thyroid disease                   | 60 (2.4%)       | 9 (2.1)          | 51 (2.5) | 0.650                  |         |
|                                   |                 |                  |         |                         | 53 (2.5) | 0.538  |

Table 1. Continue
| Variables                                | Total (n=2468) | Disease Outcome | Ward | P-value | Ward | P-value |
|------------------------------------------|----------------|-----------------|------|---------|------|---------|
|                                          |                | Deceased (n=424) | Survivor (n=2044) |       | General (n=2112) | ICU (n=356) |       |
| Other Immune deficiencies                | 38 (1.5)       | 5 (1.2)         | 33 (1.6) | 0.508   | c     | 33 (1.6) | 5 (1.4) | 0.823   | c     |
| Hysteria                                 | 32 (1.3)       | 8 (1.9)         | 24 (1.2) | 0.328   | c     | 24 (1.1) | 8 (2.2) | 0.087   | c     |
| Tuberculosis                             | 31 (1.3)       | 7 (1.7)         | 24 (1.2) | 0.422   | c     | 26 (1.2) | 5 (1.4) | 0.786   | c     |
| Anemia                                   | 29 (1.2)       | 5 (1.2)         | 24 (1.2) | 0.993   | c     | 24 (1.1) | 5 (1.4) | 0.664   | c     |
| Fatty liver                              | 105 (4.3)      | 78 (4.2)        | 87 (4.3) | 0.992   | c     | 86 (4.1) | 19 (5.3) | 0.274   | c     |
| Other Neurological disorders             | 34 (1.4)       | 6 (1.4)         | 28 (1.4) | 0.942   | c     | 30 (1.4) | 4 (1.1) | 0.657   | c     |
| Parkinson                                | 11 (0.4)       | 2 (0.5)         | 9 (0.4)  | 0.930   | c     | 9 (0.4)  | 2 (0.6) | 0.722   | c     |
| Alzheimer                                | 23 (0.9)       | 6 (1.4)         | 17 (0.8) | 0.255   | c     | 19 (0.9) | 4 (1.1) | 0.684   | c     |
| Smoke, N (%)                             |                |                 |       | 0.719   | c     |         |         | 0.347   | c     |
| Yes                                      | 114 (4.6)      | 21 (5.0)        | 93 (4.5)|         |       | 101 (4.8)| 13 (3.7)|         |       |
| Opium addiction, N (%)                   |                |                 |       | 0.309   | c     |         |         | 0.051   | c     |
| Yes                                      | 28 (1.1)       | 7 (1.7)         | 21 (1.0)|         |       | 20 (0.9) | 8 (2.2) |         |       |
| Improper use of drugs, N (%)             |                |                 |       |         |       |         |         |         |       |
| Proton-pump inhibitors (PPIs)            | 323 (13.1)     | 60 (14.2)       | 263 (12.9)| 0.476   | c     | 271 (12.8)| 52 (14.6)| 0.354   | c     |
| Nonsteroidal anti-inflammatory drug (NSAID) | 147 (6.0)  | 20 (4.7)        | 127 (6.2)| 0.236   | c     | 133 (6.3)| 14 (3.9) | 0.081   | c     |
| Antibiotics (oral agents)                | 133 (5.4)      | 34 (8.0)        | 99 (4.8) | 0.008   | c     | 79 (3.7) | 54 (15.2)| <0.001  | c     |
| Onset of symptom to hospital admission   |                |                 |       |         |       |         |         |         |       |
| Mean (SD)                                | 7.4 (3.7)      | 7.4 (3.7)       | 7.4 (3.7)| 0.986   | a     | 7.4 (3.7)| 7.2 (3.6)| 0.247   | a     |
| Median (IQR) | 7.0 (5.0 – 10.0) | 7.0 (5.0 – 10.0) | 7.0 (5.0 – 10.0) | 0.930<sup>b</sup> | 7.0 (5.0 – 10.0) | 7.0 (5.0 – 9.0) | 0.263<sup>b</sup> |
|-------------|------------------|------------------|------------------|-------------------|------------------|------------------|------------------|
| **Sign and symptoms, No. of Yes (%)** | | | | | | | |
| Fever (temperature ≥ 37.8°C) | 1439 (58.3) | 253 (59.7) | 1186 (58) | 0.532<sup>c</sup> | 1244 (58.9) | 195 (54.8) | 0.144<sup>c</sup> |
| Cough | 1868 (75.7) | 305 (71.9) | 1563 (76.5) | 0.048<sup>c</sup> | 1627 (77) | 241 (67.7) | <0.001<sup>c</sup> |
| Throat clearing | 283 (11.5) | 45 (10.6) | 238 (11.6) | 0.544<sup>c</sup> | 250 (11.8) | 33 (9.3) | 0.160<sup>c</sup> |
| Dyspnea | 1944 (78.8) | 331 (78.1) | 1613 (78.9) | 0.698<sup>c</sup> | 1646 (77.9) | 298 (83.7) | 0.014<sup>c</sup> |
| Myalgia or arthralgia | 580 (23.5) | 58 (13.7) | 522 (25.5) | <0.001<sup>c</sup> | 517 (24.5) | 63 (17.7) | 0.005<sup>c</sup> |

Table 1. Continue
| Variables                  | Total (n=2468) | Disease Outcome | P-value | Ward | P-value |
|----------------------------|----------------|-----------------|---------|------|---------|
|                            |                | Deceased (n=424) | Survivor (n=2044) |       | General (n=2112) | ICU (n=356) |
| Fatigue                    | 584 (23.7)     | 106 (25.0)      | 478 (23.4)     | 0.477 | 496 (23.5) | 88 (24.7) | 0.612 |
| Headache                   | 172 (7.0)      | 17 (4.0)        | 155 (7.6)      | 0.009 | 155 (7.3) | 17 (4.8)  | 0.079 |
| Nausea                     | 505 (20.5)     | 79 (18.6)       | 426 (20.8)     | 0.305 | 441 (20.9) | 64 (18)   | 0.209 |
| Diarrhea                   | 182 (7.4)      | 21 (5.0)        | 161 (7.9)      | 0.036 | 165 (7.8) | 17 (4.8)  | 0.043 |
| Abdominal pain             | 133 (5.4)      | 23 (5.4)        | 110 (5.4)      | 0.972 | 115 (5.4) | 18 (5.1)  | 0.764 |
| Dizziness                  | 79 (3.2)       | 9 (2.1)         | 70 (3.4)       | 0.166 | 72 (3.4)  | 7 (2)     | 0.153 |
| Parosmia                   | 246 (10)       | 44 (10.4)       | 202 (9.9)      | 0.757 | 204 (9.7) | 42 (11.8) | 0.213 |
| Anorexia                   | 416 (16.9)     | 61 (14.4)       | 355 (17.4)     | 0.136 | 362 (17.1)| 54 (15.2) | 0.358 |
| loss of consciousness      | 61 (2.5)       | 23 (5.4)        | 38 (1.9)       | <0.001 | 41 (1.9) | 20 (5.6)  | <0.001 |
| Sweating                   | 33 (1.3)       | 2 (0.5)         | 31 (1.5)       | 0.088 | 29 (1.4)  | 4 (1.1)   | 0.705 |
| Hemoptysis                 | 45 (1.8)       | 10 (2.4)        | 35 (1.7)       | 0.365 | 39 (1.8)  | 6 (1.7)   | 0.833 |
| Hallucination              | 51 (2.1)       | 7 (1.7)         | 44 (2.2)       | 0.509 | 42 (2)    | 9 (2.5)   | 0.508 |
| Chest CT images, No./total No. (%) |            |                  |            |      |          |           |
| Normal                     | 144/2468 (5.8) | 23/424 (5.4)    | 121/2044 (5.9) | 0.692 | 123/2112 (5.8) | 21/356 (5.9) | 0.955 |
| Abnormal                   | 2324/2468 (94.2) | 401/424 (94.6) | 1923/2044 (94.12) |       | 1989/2112 (94.2) | 335/356 (94.1) |         |
| Bilateral lung             | 1453/2324 (94.2) | 256/401 (64.6) | 1194/1923 (62.1) | 0.347 | 1238/1989 (62.2) | 215/335 (64.2) | 0.498 |
| Unilateral lung            | 871/2324 (35.3) | 142/401 (35.4) | 729/1923 (37.9) | 0.347 | 751/1989 (37.8) | 120/335 (35.8) | 0.498 |
| Ground lass opacity (GGO)  | 2028/2324 (94.2) | 365/401 (91.0) | 1663/1923 (86.5) | 0.013 | 1725/1989 (86.7) | 303/335 (90.4) | 0.059 |
| Pleural effusion           | 375/2324 (15.2) | 137/401 (34.2) | 238/1923 (12.4) | <0.001 | 264/1989 (13.3) | 111/335 (33.1) | <0.001 |
| Nodules                    | 315/2324 (12.8) | 129/401 (32.2) | 186/1923 (9.7) | <0.001 | 209/1989 (10.5) | 106/335 (31.6) | <0.001 |
| Consolidation              | 729/2324 (29.5) | 210/401 (54.2) | 519/1923 (27.0) | <0.001 | 506/1989 (25.4) | 223/335 (66.6) | <0.001 |
| Crazy                      | 604/2324       | 158/401         | 446/1923       | 456/1989 | 148/335       |            |      |
| paving                  | (26.0) | (39.4) | (23.2) | <0.001<sup>c</sup> | (22.9) | (44.2) | <0.001<sup>c</sup> |
|------------------------|--------|--------|--------|--------------------|--------|--------|--------------------|
| **Pericardial effusion** | 112/2324 (4.8) | 32/401 (8.0) | 80/1923 (4.2) | 0.001<sup>c</sup> | 56/1989 (2.8) | 56/335 (16.7) | <0.001<sup>c</sup> |
| **Vital sign**         |        |        |        |                    |        |        |                    |
| Oxygen saturation (SpO2) (normal range 90-92%) | 92 (88 - 95) | 88 (80 - 93) | 92 (90 - 95) | <0.001<sup>b</sup> | 92.0 (89.3 - 95.0) | 88 (80 - 93) | <0.001<sup>b</sup> |
| Systolic pressure (normal range ≤120mmHg) | 130 (110 - 146) | 135 (120 - 150) | 125 (110 - 145) | <0.001<sup>b</sup> | 126 (110 - 145) | 130 (112 - 150) | 0.010<sup>b</sup> |
| Diastolic pressure (normal range ≤80mmHg) | 80 (70 - 90) | 80 (73 - 90) | 80 (70 - 90) | <0.001<sup>b</sup> | 80 (70 - 90) | 80 (70 - 90) | 0.006<sup>b</sup> |

Table 1. Continue
| Variables                        | Total (n=2468) | Disease Outcome                  | Ward                                   |          |
|---------------------------------|----------------|----------------------------------|----------------------------------------|----------|
|                                 |                |                                 | General (n=2112)                       | ICU (n=356) |
|                                 |                | Deceased (n=424)                | Survivor (n=2044)                      |          |
|                                 |                |                                 |                                        |          |
| **Variables**                   |                | **P-value**                      | **P-value**                            |          |
| Pulse rate (PR) (normal range 60-100 BPM) | 87 (80-98)     | 88 (80-100)                      | 86 (80-98)                             | 86 (80-98) |
|                                 |                | 88 (80-100)                      |                                        | 88 (80-100) |
|                                 |                | 86 (80-98)                      |                                        | 86 (80-98) |
|                                 |                |                                 | 0.043 b                                | 0.010 b  |
|                                 |                |                                 |                                        |          |
| Respiratory rate (RR) (normal range 12-20 min) | 19 (18-20)     | 19 (18-21)                      | 19 (18-20)                             | 19 (18-21) |
|                                 |                | 19 (18-21)                      |                                        | 19 (18-21) |
|                                 |                | 19 (18-20)                      |                                        | 19 (18-21) |
|                                 |                |                                 | 0.002 b                                | <0.001 b |
|                                 |                |                                 |                                        |          |
| Temperature (normal range 36.1-37.2°C) | 38.0 (37.1-38.2) | 38.0 (37.5-38.3) | 37.9 (37.0-38.2) | <0.001 b |
|                                 |                | 37.9 (37.0-38.2) |                                        | 38.1 (37.9-38.3) |
|                                 |                |                                 |                                        | <0.001 b |
| **Blood counts parameters**     |                |                                 |                                        |          |
| White blood count (WBC) (×10^3/mm³) (normal range:4.0-11.0) | 6.6 (5.5-7.7) | 7.3 (6.2-8.4) | 6.4 (5.4-7.5) | <0.001 b |
|                                 |                | 6.4 (5.4-7.5) |                                        | 7.6 (6.5-8.7) |
|                                 |                |                                 | 0.001 b                                | <0.001 b |
| Neutrophils (NEUT) (×10³/mm³) (normal range:2.0-7.0) | 4.3 (3.6-5.2) | 4.9 (4.1-5.9) | 4.1 (3.5-5.0) | <0.001 b |
|                                 |                | 4.1 (3.5-5.0) |                                        | 5.4 (4.5-6.2) |
|                                 |                |                                 | 0.001 b                                | <0.001 b |
| Lymphocytes (LYM) (×10³/mm³) (normal range:1.0-3.0) | 1.5 (1.2-1.8) | 1.4 (1.2-1.6) | 1.5 (1.2-1.8) | 0.001 b |
|                                 |                | 1.5 (1.2-1.8) |                                        | 1.3 (1.1-1.5) |
|                                 |                |                                 | 0.001 b                                | 0.001 b  |
| Neutrophil-to-lymphocyte ratio (NLR)(normal range: 0.78-3.53) | 2.7 (2.5-3.5) | 3.4 (2.7-4.6) | 2.6 (2.5-3.2) | <0.001 b |
|                                 |                | 2.6 (2.5-3.2) |                                        | 4.6 (3.5-4.8) |
|                                 |                |                                 | <0.001 b                                | <0.001 b |
| Platelets (PLT) (×10³/mm³) (normal range:150-450) | 184 (141-244) | 176.0 (136-225) | 185.0 (142-247) | 0.024 b |
|                                 |                | 185.0 (142-247) |                                        | 175.5 (140-226) |
|                                 |                |                                 | 0.209 b                                |          |
| Hemoglobin (Hb) (×gr/dL) (normal range:[Males:13.5-17.5],[Females:12.0-15.5]) | 13.3 (11.9-14.6) | 13.0 (11.7-14.4) | 13.3 (11.9-14.6) | 0.011 b |
|                                 |                | 13.3 (11.9-14.6) |                                        | 13.2 (11.9-14.5) |
|                                 |                |                                 | 0.598 b                                |          |
| **Inflammatory markers**         |                |                                 |                                        |          |
| C-reactive protein (CRP)(× mg/L)(normal range≤10) | 51.0 (26.0-73.8) | 56.0 (29.0-85.8) | 50.0 (25.0-72.0) | <0.001 b |
|                                 |                | 50.0 (25.0-72.0) |                                        | 50.7 (26.0-72.0) |
|                                 |                |                                 | <0.001 b                                | 0.006 b  |
| Erythrocyte Sedimentation Rate (ESR)(×mm/hr)(normal range:[Males≤20], [Females≤30]) | 39.0 (25.0-63.8) | 73.0 (37.3-84.0) | 35.5 (25.0-52.0) | <0.001 b |
|                                 |                | 35.5 (25.0-52.0) |                                        | 37.0 (25.0-56.0) |
|                                 |                |                                 | <0.001 b                                | 0.001 b  |
### Biochemical Parameters

| Parameter                        | Value                      | Value                      | Value                      | Value                      | Value                      | Value                      |
|----------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Serum creatinine (CR) mg/dL      | 1.1 (1.0 - 1.4)            | 1.2 (1.0 - 1.5)            | 1.1 (1.0 - 1.4)            | 0.192                      | 1.1 (1.0 - 1.4)            | 1.2 (1.0 - 1.4)            | 0.382                      |
| Creatinine phosphokinase (CPK) ×U/L [Males:39-308][Females:26-192] | 218 (158 - 315)            | 264.0 (178. - 319)         | 215.0 (156 - 315)          | <0.001                     | 215.0 (156 - 315)          | 274.0 (178 - 342)          | <0.001                     |
| High-sensivity Troponin T ng/L [Males≤22][Females≤14] | 24.6 (16.2 - 34.6)        | 37.9 (27.3 - 49.2)          | 22.5 (16.2 - 31.2)         | <0.001                     | 23.1 (16.2 - 33.8)          | 37.4 (27.4 - 47.1)          | <0.001                     |

### Coagulation profile

| Parameter                        | Value                      | Value                      | Value                      | Value                      | Value                      | Value                      |
|----------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Prothrombin time (PT) seconds    | 15.0 (14.0 - 16.2)         | 15.6 (14.4 - 17.0)         | 14.9 (13.9 - 16.0)         | <0.001                     | 14.9 (14.0 - 16.1)         | 15.3 (14.3 - 16.9)         | <0.001                     |
| Partial Thromboplastin Time (PTT) seconds | 35.0 (30.0-39.4)        | 37.0 (30.6 - 40.2)         | 34.2 (30.0 - 39.1)         | <0.001                     | 34.6 (30.0 - 39.1)         | 37.0 (30.8 - 40.3)         | <0.001                     |
| International normalized ratio (INR) | 1.3 (1.2-1.4)             | 1.3 (1.2 - 1.4)            | 1.3 (1.1 - 1.4)            | 0.021                      | 1.3 (1.2 - 1.4)            | 1.3 (1.2 - 1.4)            | 0.859                      |

### Liver function test

| Parameter                        | Value                      | Value                      | Value                      | Value                      | Value                      | Value                      | Value                      | Value                      |
|----------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Alanine aminotransferase ALT (U/L) [normal range:10-45] | 34.0 (25.0 - 49.0)        | 52.0 (34.0 - 62.8)         | 31.0 (25.0 - 42.0)         | <0.001                     | 31.0 (25.0 - 43.0)         | 51.0 (34.0 - 61.0)         | <0.001                     | 51.0 (34.0 - 61.0)         |
| Aspartate aminotransferase AST (U/L) [normal range:10-40] | 39.0 (30.0 - 52.0)        | 58.5 (37.0 - 75.0)         | 37.0 (29.0 - 49.0)         | <0.001                     | 37.0 (29.0 - 49.0)         | 59.0 (40.0 - 76.0)         | <0.001                     | 59.0 (40.0 - 76.0)         |

Note: Data were expressed as mean (standard deviation) and median (IQR) for symmetric and asymmetric numeric variables. Categorical variables were shown as No. (%). P-values denoted a) the comparison of mean variables between survivor and non-survivor cases using independent t-test, b) the mean rank difference of variables between survivor and non-survivor using Mann Whitney test, and c) the relation between baseline variables and survivor/non-survivor patients using Pearson chi-squared. * Pregnancy percentage was calculated among females.

The most prevalent comorbidity seen in Hypertension (HTN) (31.3%), Diabetes Mellitus (DM) (27.5%), Hyperlipidemia (HLP) (13.0%), and Ischemic heart disease (IHD) (10.5%). An overlap was seen in Fig. 1.B1 among patients where for example, 14 of them had HTN, DM, and Chronic Obstructive Pulmonary Disease (COPD) in their
past medical history. The most prevalent comorbidities was recorded among 51–80 years old patients, especially 61–70 years old ones (Fig. 1.B2).

Patients hospitalization was occurred a mean of 7.4 ± 3.7 days after the onset of symptoms. The most common symptoms of patients were dyspnea (78.8%), cough (75.7%), fever (58.3%), fatigue (23.7%), and myalgia or arthralgia (23.5%). 927(37.5%) concurrent fever, cough, and dyspnea, and also 13 (0.52%) presented all intestinal-related manifestation upon admission day (Fig. 1.A).

At triage, vital signs included oxygen saturation, respiratory rate, and temperature were reported as a median of 92 % (88–95), 19 (18–20), and 38.0°C (37.1–38.2), respectively while 92.3% of them underwent oxygen therapy. Higher Blood pressure, Pulse Rate, Respiratory Rate, and Temperature and lower Oxygen Saturation were detected among death cases.

Median white blood cell was reported 6.6 (5.5–7.7) with the median of 1.5 (1.2–1.8) for lymphocytes. Concentrations of C-reactive protein (median: 51.0 (26.0–73.8)), Erythrocyte Sedimentation Rate (median: 39.0 (25.0–63.8)), high-sensitivity Troponin (median: 24.6 (16.2–34.6)) were elevated in most patients. Significantly Higher range of inflammatory markers, coagulation profile, and liver function tests were observed among serious patients.

Chest HRCT-scan was taken from all participants that reported by the radiologist in which Just 144 (5.8%) of patients had normal radiological findings. Most of the patients (94.2%) presented radiological features bilaterally. The most frequent features reported by the radiologists were Ground Glass Opacities (GGO) (94.2%) and consolidations (29.5%).

Table 2 described treatment protocols and their association with survival and mortality. During hospitalization, patients were supported by respiratory facilities, 555(22.5%) of whom by means of nasal cannula, 287(11.6%) via simple face mask, 1437(58.2%) through face mask with reserve bag, and 210(8.5%) with the help of intubation.
### Table 2
Intervention results of patients with COVID-19

| Variables                                | Total (n = 2468) | Disease Outcome | P-value |
|-------------------------------------------|------------------|-----------------|---------|
|                                           |                  | Deceased (n = 424) | Survivor (n = 2044) |
| Respiratory facilities, No (%)            |                  |                 |         |
| None or Unknown                           | 189 (7.7)        | 51 (12)         | 138 (6.8) |
| Nasal                                     | 555 (22.5)       | 52 (12.3)       | 503 (24.6) |
| Simple face mask                          | 287 (11.6)       | 44 (10.4)       | 243 (11.9) |
| Reserve bag                               | 1437 (58.2)      | 277 (65.3)      | 1160 (56.8) |
| Intubation                                | 210 (8.5)        | 136 (32.1)      | 74 (3.6) |

### Drug, N (%)

| Drug, N (%)                                | Total (n = 2468) | Disease Outcome | P-value |
|--------------------------------------------|------------------|-----------------|---------|
| Hydroxychloroquine (PO)                    | 2012 (81.5)      | 342 (80.7)      | 1670 (81.7) |
| Kaletra (Lopinavir/ritonavir) (PO)         | 1647 (66.7)      | 257 (60.6)      | 1390 (68) |
| Oseltamivir (PO)                           | 1835 (74.4)      | 226 (53.3)      | 1609 (78.7) |
| Paracetamol (Inj)                          | 2015 (81.6)      | 337 (79.5)      | 1678 (82.1) |
| Naproxen (PO)                              | 947 (38.4)       | 145 (34.2)      | 802 (39.2) |
| Ribavirin (PO)                             | 381 (15.4)       | 128 (30.2)      | 253 (12.4) |
| Pantoprazole (PO)                          | 1211 (49.1)      | 215 (50.7)      | 996 (48.7) |
| Ceftriaxone (Inj)                          | 1687 (68.4)      | 262 (61.8)      | 1425 (69.7) |
| Metoclopramide (Inj)                       | 105 (4.3)        | 14 (3.3)        | 91 (4.5) |
| Ondansetron (Inj)                          | 419 (17)         | 70 (16.5)       | 349 (17.1) |
| Diphenhydramine (PO)                       | 651 (26.4)       | 98 (23.1)       | 553 (27.1) |
| Meropenem (Inj)                            | 904 (36.6)       | 227 (53.5)      | 677 (33.1) |
| Linezolid (PO)                             | 230 (9.3)        | 69 (16.3)       | 161 (7.9) |
| Atrovent (Ipratropium bromide) (Inh)       | 451 (18.3)       | 94 (22.2)       | 357 (17.5) |

*Note: P-values marked with ‘c’ indicate statistical significance.*
| Variables                                      | Total (n = 2468) | Disease Outcome                      | P-value |
|-----------------------------------------------|------------------|--------------------------------------|---------|
|                                               |                  | Deceased (n = 424) | Survivor (n = 2044) |         |
| Atorvastatin (PO)                             | 447 (18.1)       | 91 (21.5) | 356 (17.4) | 0.049 c |
| Vancomycin (Inj)                              | 1151 (46.6)      | 247 (58.3) | 904 (44.2) | < 0.001 c |
| Dexamethasone (Inj)                           | 337 (13.7)       | 88 (20.8) | 249 (12.2) | < 0.001 c |
| Salbutamol (Inh)                              | 590 (23.9)       | 121 (28.5) | 469 (22.9) | 0.014 c |
| Combivent (Ipratropium bromide/salbutamol) (Inh) | 296 (12)        | 77 (18.2) | 219 (10.7) | < 0.001 c |
| Pulmicort (Budesonide) (Inh)                  | 316 (12.8)       | 63 (14.9) | 253 (12.4) | 0.164 c |
| Levofoxacin (PO)                              | 297 (12)         | 47 (11.1) | 250 (12.2) | 0.509 c |
| Enoxaparin sodium (Inj)                       | 963 (39)         | 141 (33.3) | 822 (40.2) | 0.007 c |
| Heparin (Inj)                                 | 373 (15.1)       | 114 (26.9) | 259 (12.7) | < 0.001 c |
| Aspirin (PO)                                  | 290 (11.8)       | 71 (16.7) | 219 (10.7) | < 0.001 c |
| N-acetyl cysteine (Inj)                       | 309 (12.5)       | 65 (15.3) | 244 (11.9) | 0.055 c |
| Clindamycin (PO)                              | 32 (1.3)         | 6 (1.4)   | 26 (1.3)   | 0.813 c |
| Azithromycin (PO)                             | 1624 (65.8)      | 238 (56.1) | 1386 (67.8) | < 0.001 c |
| Dextromethorphan (PO)                         | 114 (4.6)        | 22 (5.2)  | 92 (4.5)   | 0.539 c |
| Remdesivir (Inj)                              | 123 (5)          | 42 (9.9)  | 81 (4)     | < 0.001 c |
| Clopidogrel (PO)                              | 88 (3.6)         | 22 (5.2)  | 66 (3.2)   | 0.048 c |
Table 2
Continue

| Variables                                      | Total (n = 2468) | Disease Outcome | Survivor (n = 2044) | P-value |
|------------------------------------------------|-----------------|-----------------|---------------------|---------|
|                                                 |                 | Deceased (n = 424) |                     |         |
| Interferon Beta-1A (Inj)                        | 175 (7.1)       | 41 (9.7)        | 134 (6.6)           | 0.023 c |
| Fluconazole (PO)                                | 70 (2.8)        | 14 (3.3)        | 56 (2.7)            | 0.526 c |
| Prednisolone (PO)                               | 140 (5.7)       | 36 (8.5)        | 104 (5.1)           | 0.006 c |
| Promethazine (Inj)                              | 82 (3.3)        | 12 (2.8)        | 70 (3.4)            | 0.534 c |
| Seroflo(Fluticasone/salmeterol) (Inh)           | 90 (3.6)        | 18 (4.2)        | 72 (3.5)            | 0.470 c |
| Ciprofloxacin (PO)                              | 348 (14.1)      | 70 (16.5)       | 278 (13.6)          | 0.117 c |
| Vitamin B- Complex (Inj)                        | 266 (10.8)      | 60 (14.2)       | 206 (10.1)          | 0.014 c |
| Vitamin C (Inj)                                 | 199 (8.1)       | 54 (12.7)       | 145 (7.1)           | < 0.001 c |
| Vitamin D (Inj)                                 | 139 (5.6)       | 35 (8.3)        | 104 (5.1)           | 0.010 c |
| MgSo4 (Inj)                                     | 237 (9.6)       | 41 (9.7)        | 196 (9.6)           | 0.959 c |
| Dimenhydrinate (PO)                             | 260 (10.5)      | 37 (8.7)        | 223 (10.9)          | 0.183 c |
| Selenium (PO)                                   | 65 (2.6)        | 26 (6.1)        | 39 (1.9)            | < 0.001 c |
| Clidinium-C (PO)                                | 55 (2.2)        | 4 (0.9)         | 51 (2.5)            | 0.049 c |
| Bromhexine (PO)                                 | 102 (4.1)       | 21 (5)          | 81 (4)              | 0.351 c |
| CaCo3 (PO)                                      | 82 (3.3)        | 23 (5.4)        | 59 (2.9)            | 0.008 c |
| Amantadin (PO)                                  | 129 (5.2)       | 26 (6.1)        | 103 (5)             | 0.357 c |
| Imipenem (Inj)                                  | 150 (6.1)       | 23 (5.4)        | 127 (6.2)           | 0.536 c |
| Piperacillin (Inj)                               | 30 (1.2)        | 6 (1.4)         | 24 (1.2)            | 0.680 c |
| Atazanavir (PO)                                 | 78 (3.2)        | 20 (4.7)        | 58 (2.8)            | 0.044 c |
| Dialysis, No. of yes (%)                        | 75 (3)          | 40 (9.4)        | 35 (1.7)            | < 0.001 c |
| Plasmapheresis, No. of yes (%)                   | 28 (1.1)        | 17 (4)          | 11 (0.5)            | < 0.001 c |

Note: Data were expressed as mean (standard deviation) and median (IQR) for symmetric and asymmetric numeric variables. Categorical variables were shown as No. (%). P-values denoted a) the comparison of mean variables between survivor and non-survivor cases using independent t-test, b) the mean rank difference of variables between survivor and non-survivor using Mann Whitney test, and c) the relation between baseline variables and survivor/non-survivor patients using Pearson chi-squared. PO = per os (orally), Inj = injection, Inh = inhalation.
| Variables                             | Total (n = 2468) | Disease Outcome | P-value |
|---------------------------------------|------------------|-----------------|---------|
|                                       |                  | Deceased (n = 424) | Survivor (n = 2044) |         |
| Platelet transfusion, No. of yes (%)  | 8 (0.3)          | 1 (0.2)         | 7 (0.3)       | 0.725 c |
| Blood transfusion, No. of yes (%)     | 331 (13.4)       | 66 (15.6)       | 265 (13)      | 0.153 c |

Note: Data were expressed as mean (standard deviation) and median (IQR) for symmetric and asymmetric numeric variables. Categorical variables were shown as No. (%). P-values denoted a) the comparison of mean variables between survivor and non-survivor cases using independent t-test, b) the mean rank difference of variables between survivor and non-survivor using Mann Whitney test, and c) the relation between baseline variables and survivor/non-survivor patients using Pearson chi-squared. PO = per os (orally), Inj = injection, Inh = inhalation.

Antibacterial agents were prescribed for most of patients, namely, Ceftriaxone for 1687 (68.4%), Meropenem for 904 (36.6%), and Vancomycin for 1151 (46.6%) patients.

Besides, Antiviral agents also were advised for most patients, predominantly, 2012 (81.5%) received Hydroxychloroquine, 1835 (74.4%) received Oseltamivir, 1647 (66.7%) received Kaletra, 381 (15.4%) received Ribavirin, and 123 (5%) received Remdesivir. Immunosuppressants were applied to patients including Dexamethasone in 337 (13.7%), and Prednisolone in 140 (5.7%). Furthermore, Immunomodulators such as Interferons were administered for 157 (7.1%) of cases. Therapeutic procedures like kidney replacement therapy and Plasmaphresis were performed for 3% and 1.1% of critically ill patients, respectively.

The most remarkable adverse events and outcomes of COVID-19 is presented in Table 3. Weight loss (9.3%) defined as ≥ 5% in comparison to initial weight, myocardial injuries (6.6%) diagnosed by triple-elevation of Troponin level and electrocardiogram and echocardiogram findings, kidney injury (6%), and abnormal bleeding (5.1%) were reported as the most frequent adverse events resulted from COVID-19. During the study, 424 (17.2%) of patients died in hospital following a median of 5 days (3–10) hospitalization. This range included 220 (61.8%) of 356 patients and 204 (9.7%) of 2112 patients who were admitted to Intensive Care Unit (ICU) and general ward, respectively. 2044 (82.8%) of patients were discharged alive after a median of 5 days (3–10) of hospitalization. During the 30-day post-discharge follow-up, 148 (6.0%) of 2468 patients readmitted and 25 (1.2%) of 2034 discharged cases died. Full recovery from symptoms after discharge took a median of 14 (10–18) days, although the manifestation remained in 5.3% of cases for more than 30 days. Our results revealed that just 26 (5.8%) of 450 Cardiopulmonary resuscitation (CPR)s were successful.
| Variables                                    | Total             |
|---------------------------------------------|-------------------|
|                                             | (n = 2468)        |
| **Readmission (≤ 30 days post-discharge), No. of yes (%)** | 148 (6.0)         |
| **Death in hospital, No. of yes (%)**       | 424 (17.2)        |
| **Death out of hospital (≤ 30 days post-discharge), No. of yes (%)** | 25/2034 (1.2)*    |
| **Death in general ward, No. of yes (%)**    | 204/2112 (9.7)    |
| **Death in ICU, No. of yes (%)**            | 220/356 (61.8)    |
| **CVA (ischemic type), No. of yes (%)**      | 41 (1.7)          |
| **Myocardial infarction, No. of yes (%)**    | 36 (1.5)          |
| **DVT, No. of yes (%)**                     | 69 (2.8)          |
| **Kidney injury, No. of yes (%)**           | 148 (6)           |
| **Alopecia, No. of yes (%)**                | 46 (1.9)          |
| **Myocardial injury, No. of yes (%)**        | 164 (6.6)         |
| **Abnormal bleeding, No. of yes (%)**        | 126 (5.1)         |
| **Weight loss, No. of yes (%)**              | 187 (9.3)**       |
| **Skin problems (Acro-ischemic lesions), No. of yes (%)** | 44 (1.8)         |
| **Duration of hospitalization, median (IQR)**|                   |
| Total with death                            | 5.0 (3.0–10.0)    |
| Total with discharge                        | 5.0 (3.0–7.0)     |
| General with death                          | 4.0 (2.0–6.0)     |
| General with discharge                       | 5.0 (3.0–7.0)     |
| ICU with death                              | 5.0 (2.0–9.0)     |
| ICU with discharge                           | 5.0 (2.0–7.8)     |
| **Successful CPR in hospital, No. of yes (%)** | 26/450 (5.8)**    |
| **Full time recovery of symptoms after discharge** |                   |
| Median (Q1 – Q3)                            | 14 (10–18)        |
| Existence of symptoms after 30 days of discharge, No. of yes (%) | 106/2009 (5.3)**** |
Variables

| Total (n = 2468) |
|------------------|
| Note: Data were expressed as mean (standard deviation) and median (IQR) for symmetric and asymmetric numeric variables. Categorical variables were shown as No. (%). P-values denoted a) the comparison of mean variables between survivor and non-survivor cases using independent t-test, b) the mean rank difference of variables between survivor and non-survivor using Mann Whitney test, and c) the relation between baseline variables and survivor/non-survivor patients using Pearson chi-squared. * All deaths out of hospital were occurred between discharge patients; ** all weight loss cases are related to patients who survived. *** The denominator is the summation of CPR cases and number of deaths; **** the denominator is those who were discharged from the hospital and did not die outside the hospital for a month. ICU = intensive care unit, CVA = cerebrovascular accident, DVT = deep venous thrombosis, CPR = cardiopulmonary resuscitation |

On single and multiple Cox regression model, the significant risk factors of death due to COVID-19 like: age, gender, a number of comorbidities, symptoms, paraclinical data and treatment protocols were found, presented in detail in Appendix 1.

The analysis of the final Cox regression model (Fig. 2) revealed that the hazard of death due to COVID-19 significantly increased by more than five-fold per each year of increase in 70–79 age group (HR = 5.25, 95%CI: 2.79, 9.87), by 74% in smokers (HR = 1.74, 95%CI: 1.06, 2.85), and by nearly three-fold in patients with congestive heart failure (HR = 2.92, 95%CI: 1.44, 5.95). The therapeutic agents significantly decreased risk of death, by 74% with Lopinavir/Ritonavir (HR = 0.74, 95%CI: 0.60, 0.92), 35% with Oseltamivir (HR = 0.35, 95%CI: 0.29, 0.43), 66% with Azithromycin (HR = 0.66, 95%CI: 0.53, 0.82), and more than half among patients who received Interferon (HR = 0.55, 95%CI: 0.39, 0.77). On the contrary, surprisingly, the hazard of death increased by more than two-fold when it comes to Plasmaphresis (HR = 2.37, 95%CI: 1.39, 4.03), and by 32% and 34% in patients who received Aspirin (HR = 1.32, 95%CI: 1.02, 1.71) and Ribavirin (HR = 1.34, 95%CI: 1.05, 1.70), respectively. Notably, the hazard ratio of each factor was assessed considering the effect of all other variables.

Figure 3 showed the Kaplan-Meier survival curve with the 95% confidence interval and representation of the censoring time. Accordingly, the survival probability was 0.14 and 0.12 in the two groups of crypt > 59 and ≥ 59 years, respectively, after thirty days of hospitalization.

**Discussion**

To the extent of our knowledge, this is the first cohort study of COVID-19 in the case of gathered precise information from admitted patients in the first center of SARS-CoV-19 in Iran. 2468 COVID-19 patients were admitted to four hospitals of Qom during the first months of the Iran’s COVID-19 outbreak. Our findings provided informative and stringent demographic data, paraclinical findings, therapeutic approaches, disease outcomes, and post-discharge follow-up in details. However, multivariable analysis were performed to define the risk factors of death subject to COVID-19.
The majority of patients were men having the mean age of 57.9 ± 17.6 years and hypertension and diabetes, nearly half of which had upper than normal weight, which was in line with China (8) and USA pattern (5). The most prevalent symptoms were dyspnea (78.8%), cough (75.7%), and fever (58.3%), which are consistent with Ashraf et al (2) and Guan et al (9). These data may represent fever as a minor symptom of COVID-19, whilst cough and dyspnea are major ones. 92.3% of patients received respiratory facilities while 14.42% of whom were admitted to ICU. In the course of the study, 17.2% and 1.2% of patients died in hospital and out of hospital, respectively, which is similar to Germany and France (7), but lower than UK with 39% of mortality (10). Surely, the inconsistency result ascribes insignificant differences between countries in population demographic data and health care systems. The mortality rate was reported 2.3% at the onset of COVID-19 epidemic (11). This controversy may result from investigating the patients until 30-days after discharge, and just admitted patients were participated.

356 (14.42%) out of 2468 participants were critically ill and admitted to ICU, which is similar to reports from China (9, 12), Italy (13), and New York City (14). 92.3% of patients required respiratory facilities which is consistent with Italy reports, but it is higher than China (8, 9, 12, 15), New York (14), and Washington state (16). These high rates of critically ill patients requiring respiratory support and ICU admission, emphasizes the severity of the disease in Iran and urgent need for Iran’s hospital conveniences.

In this cohort study, 424 (17.2%) patients died in hospital and 2044 (82.8%) were discharged. The significant risk factors of death related to COVID-19 were ageing, male gender, HTN, CHF, CVA, CKD, increasing ESR, PT, WBC, liver function tests, and decreasing Oxygen saturation. Particularly, our data showed the higher survival rate for younger than 59 years, which is in line with Germany reports (7). Similarly, Cummings et al reported that older age, cardiopulmonary underlying diseases, and higher ranges of D-dimer, ALT, CRP, and Troponin are regarded as risk factors of poor outcomes (14). The abnormal level of Prothrombin might result from procoagulant state in COVID-19 (17). Abnormal serum Creatinine levels might be secondary to direct kidney injury or fluid imbalance, and also higher levels of WBC might be a clue of bacterial super-infection.

Similarly to data from China (12) and Italy (18), Hypertension was associated with poor in-hospital outcomes. In consistent with CVA as a risk factor of death in our study, an analysis of Aggawal G et al revealed a 2.5-fold increase in severity of COVID-19 illness among patients with underlying cerebrovascular disease (19).

55.2% of admitted patients were overweight while critically deceased cases had higher BMI mean in comparison with the survivors. These data are similar to UK (20) and USA (14), where obesity has been related with higher rates of ICU admission and mortality. Although obesity is an exacerbating factor for many diseases including HTN, DM, CVA, liver and renal dysfunctions, confirming studies needs to be performed to approve that association.

Non-survivors had higher range of Blood pressure, Temperature, Pulse rate, Respiratory rate, and lower Oxygen saturation compared to These findings illustrates that patients’ abnormal vital signs might be prognostic factors of severity.

Anti-viral agents were administered to all patients. Lopinavir/Ritonavir and Remdisivir played a significant role in patients’ survival. Ashraf et al reported the positive effect of Kaletra on patients’ outcomes (2). It should be noted that the US National Institute of Allergy and Infectious Diseases approved an emergency administration of Remdesivir for critical cases of COVID-19 inpatients. The efficacy of administrating Hydroxychlorquine with respect to COVID-19 patients remains to be understood. The revealed information from the USA have not disclosed the
beneficial effect of Hydroxychloroquine for COVID-19 inpatients(21). Interferon was one of the immunomodulators with remarkable effects on COVID-19 patients’ survival in our study. Interferons (IFN) strengthen the immune system by antiviral and immunomodulatory activities(22). Nile et al reported the benefits of IFNs against SARS-CoV-2, alone or in combination with the other anti-viral agents(23). The most challenging therapeutic agent would be Plasmaphresis, which increases the hazard of death on the contrary with other studies in which it has reported the beneficial effect of a COVID-19 convalescent plasma transfusion on the treatment of critically ill COVID-19 cases through neutralization of SARS-CoV-2 and inhibition of cytokine storm(24–26). However, we evaluated this effect beside other co-factors, and just 1.1% of the participants underwent Plasmaphresis, therefore, it requires further studies with larger study population.

One of the most striking features of this study would be a 30-day post-discharge follow-up indicated 6.0% readmission, 1.2% post-discharge death, the median of 14 days of recovery of symptoms, and existence of symptoms in 5.3% of patients after 30 days of discharge. Similarly, Ashraf et al reported 8.6% of readmission and 4.3% of death after discharge(2). These data emphasizes the symptoms relapse and the importance of close follow-up after discharge.

**Conclusion**

To our knowledge, this study is the first study of COVID-19 with detailed information of participants in Qom, the main source of SARS-CoV-19 transmission in the Middle-East.

To wrap up, various outcomes of COVID-19 among different countries attribute to different demographic data and health care systems. This disease has the potential to aggravate with regard to identified risk factors. As a result, at-risk patients need to be looked after specifically in favor of saving more lives.

**Declarations**

**Acknowledgments**

The authors would like to thank Qom University of Medical sciences for access to the patient’s documents and medical records.

**Authors’ contributions**

MAP, HY and SHA developed the original idea for the study. HY, HF, NN, ZH, MY, ZS, and EM contributed in data gathering, data extraction and checking the validity of laboratory results in documents. MAP and MA conducted the analysis. NT, MAP HY wrote the first draft of the manuscript. All authors reviewed and accepted the paper prior to submission.

**Funding**

Not received

**Availability of data and materials**

Data would be available upon reasonable request by contacting the corresponding author.

**Ethics approval and consent to participate**
This study was approved by the Qom University of medical sciences ethics committee (IR.MUQ.REC.1399.013). Informed contest was taken from all participants

**Consent for publication**

Not applicable

**Competing interests**

The authors declare they have no conflict of interest.

**Abbreviations**

SARS-CoV-2: Severe acute respiratory syndrome corona virus 2, PCR: polymerase chain reaction, ICU: intensive care unit, WHO: world health organization, CDC: Centers for Disease Control and Prevention, CBC: complete blood count diff, CRP: C-reactive protein, ESR: Erythrocyte sedimentation rate, RT-PCR: reverse-transcriptase-polymerase chain-reaction, HTN: Hypertension, DM: Diabetes Mellitus, HLP: Hyperlipidemia, IHD: Ischemic heart disease, COPD: Chronic Obstructive Pulmonary Disease, GGO: Ground Glass Opacities, CPR: Cardiopulmonary resuscitation, IFN: Interferons, HRCT: high resolution computed tomography

**References**

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020.
2. Ashraf MA, Shokouhi N, Shirali E, Davari-tanha F, Memar O, Kamalipour A, et al. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. medRxiv. 2020.
3. Covid W. coronavirus pandemic. 2020.
4. Arab-Mazar Z, Sah R, Rabaan AA, Dhama K, Rodriguez-Morales AJ. Mapping the incidence of the COVID-19 hotspot in Iran—Implications for Travellers. Travel Medicine and Infectious Disease. 2020.
5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020.
6. Khoshnood RJ, Ommi D, Zali A, Ashrafi F, Vahidi M, Azhide A, et al. Epidemiological Characteristics, Clinical Features, and Outcome of COVID-19 Patients in Northern Tehran, Iran; a Cross-Sectional Study. Advanced Journal of Emergency Medicine. 2020.
7. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. The Lancet Respiratory Medicine. 2020;8(9):853–62.
8. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020.
9. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708–20.
10. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. bmj. 2020;369.

11. Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2020;41(2):145.

12. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239–42.

13. Giacomo G, Antonio P, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy. 2020.

14. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. 2020.

15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020.

16. Arentz M, Yim E, Klaff L. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State [published online March 19, 2020]. JAMA doi.10.

17. Ranucci M, Ballotta A, Di Dedda U. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome.[published online ahead of print, 2020 Apr 17]. J Thromb Haemost.

18. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama [Internet]. 2020;1–8. 2020.

19. Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature. International Journal of Stroke. 2020;15(4):385–9.

20. Audit I. ICNARC report on COVID-19 in critical care. April. 2020;10:2020.

21. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine. 2020.

22. Wang BX, Fish EN, editors. Global virus outbreaks: Interferons as 1st responders. Seminars in immunology; 2019: Elsevier.

23. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine & Growth Factor Reviews. 2020.

24. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of medical virology. 2020;92(10):1890–901.

25. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020;117(17):9490-6.

26. Keith P, Day M, Choe C, Perkins L, Moyer L, Hays E, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE open medical case reports. 2020;8:2050313X20933473.

Figures
Figure 1

(A). Euler diagram of overlapped symptoms. (B): 1. Euler diagram of overlapped comorbidities, 2. Heatmap of number of comorbidities among different age groups.
### Figure 2

**Hazard of death due to SARS-CoV-2**

| Variable               | N Events | Event Rate | Hazard ratio | p     |
|------------------------|----------|------------|--------------|-------|
| **Gender**             |          |            |              |       |
| Female                 | 936      | 137        | Reference    |       |
| Male                   | 1214     | 202        | 1.16 (0.92, 1.45) | 0.206 |
| **Age**                |          |            |              |       |
| <30                    | 420      | 17         | Reference    |       |
| 40-49                  | 367      | 46         | 2.20 (1.26, 3.84) | 0.006 |
| 50-59                  | 472      | 55         | 1.76 (1.01, 3.07) | 0.044 |
| 60-69                  | 516      | 104        | 3.08 (1.82, 5.20) | <0.001 |
| 70-79                  | 67       | 24         | 5.25 (2.79, 9.87) | <0.001 |
| ≥80                    | 308      | 93         | 3.39 (1.98, 5.79) | <0.001 |
| **Smoker**             |          |            |              |       |
| No                     | 2045     | 329        | Reference    |       |
| Yes                    | 105      | 19         | 1.74 (1.08, 2.85) | 0.027 |
| **HTN**                |          |            |              |       |
| No                     | 1516     | 207        | Reference    |       |
| Yes                    | 634      | 132        | 1.18 (0.93, 1.50) | 0.170 |
| **CHF**                |          |            |              |       |
| No                     | 2128     | 331        | Reference    |       |
| Yes                    | 22       | 8          | 2.92 (1.44, 5.95) | 0.003 |
| **COPD**               |          |            |              |       |
| No                     | 2074     | 320        | Reference    |       |
| Yes                    | 76       | 19         | 0.94 (0.57, 1.56) | 0.821 |
| **DM**                 |          |            |              |       |
| No                     | 1581     | 226        | Reference    |       |
| Yes                    | 569      | 113        | 1.61 (0.78, 2.29) | 0.067 |
| **CVA**                |          |            |              |       |
| No                     | 2102     | 325        | Reference    |       |
| Yes                    | 48       | 14         | 1.58 (0.90, 2.76) | 0.112 |
| **BHP**                |          |            |              |       |
| No                     | 1891     | 290        | Reference    |       |
| Yes                    | 259      | 49         | 1.13 (0.83, 1.54) | 0.429 |
| **Tuberculosis**        |          |            |              |       |
| No                     | 2102     | 325        | Reference    |       |
| Yes                    | 48       | 14         |             |       |

**Table:**

| Variable               | N Events | Event Rate | Hazard ratio | p     |
|------------------------|----------|------------|--------------|-------|
| Antibiotic             | 2535     | 390        | Reference    |       |
| Yes                    | 153      | 24         | 0.69 (0.47, 1.06) | 0.049 |
| No                     | 821      | 167        | Reference    |       |
| Yes                    | 1647     | 257        | 0.74 (0.60, 0.92) | 0.006 |
| Oseltamivir            | 633      | 198        | Reference    |       |
| Yes                    | 1835     | 226        | 0.35 (0.29, 0.43) | <0.001 |
| No                     | 2087     | 296        | Reference    |       |
| Yes                    | 381      | 128        | 1.34 (0.91, 1.96) | 0.113 |
| Ceftriaxone            | 781      | 162        | Reference    |       |
| Yes                    | 1687     | 262        | 1.04 (0.83, 1.31) | 0.719 |
| No                     | 2049     | 334        | Reference    |       |
| Yes                    | 419      | 70         | 0.90 (0.69, 1.17) | 0.418 |
| Coubicide              | 2172     | 347        | Reference    |       |
| Yes                    | 296      | 77         | 1.48 (1.14, 1.92) | 0.004 |
| No                     | 1505     | 283        | Reference    |       |
| Yes                    | 963      | 141        | 0.90 (0.72, 1.14) | 0.386 |
| Heparin                | 2095     | 310        | Reference    |       |
| Yes                    | 373      | 114        | 1.20 (0.94, 1.52) | 0.140 |
| No                     | 2178     | 333        | Reference    |       |
| Yes                    | 290      | 71         | 1.32 (1.02, 1.71) | 0.036 |
| NAC                    | 2159     | 359        | Reference    |       |
| Yes                    | 309      | 45         | 0.89 (0.68, 1.18) | 0.432 |
| Aspirin                | 844      | 186        | Reference    |       |
| Yes                    | 1624     | 238        | 0.66 (0.53, 0.82) | <0.001 |
| Remdesivir             | 2345     | 382        | Reference    |       |
| Yes                    | 123      | 42         | 1.02 (0.72, 1.44) | 0.923 |
| No                     | 389      | 134        | Reference    |       |
| Yes                    | 175      | 41         | 0.55 (0.39, 0.77) | <0.001 |
| VHC                    | 2289     | 379        | Reference    |       |
| Yes                    | 199      | 54         | 0.87 (0.64, 1.19) | 0.384 |
| No                     | 2803     | 398        | Reference    |       |
| Yes                    | 65       | 26         | 1.12 (0.71, 1.76) | 0.632 |
| Plasmapheresis         | 2440     | 407        | Reference    |       |
| Yes                    | 28       | 17         | 2.37 (1.39, 4.03) | 0.002 |

**Note:** The hazard ratio and p-value are calculated using statistical methods to assess the risk of death due to SARS-CoV-2 in different conditions or treatments.
Figure 3

Kaplan-Meier based survival curve according to hospital admission due to COVID-19 among two age groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Appendix1.docx